Investment Analysts’ Recent Ratings Updates for Abivax (ABVX)

Abivax (NASDAQ: ABVX) has recently received a number of price target changes and ratings updates:

• 12/16/2025 – Abivax had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $142.00 price target on the stock.
• 12/16/2025 – Abivax had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 12/16/2025 – Abivax had its price target raised by analysts at Citizens Jmp from $114.00 to $131.00. They now have a “market outperform” rating on the stock.
• 12/13/2025 – Abivax was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/24/2025 – Abivax was given a new $140.00 price target on by analysts at Truist Financial Corporation.
• 11/24/2025 – Abivax is now covered by analysts at Truist Financial Corporation. They set a “buy” rating and a $140.00 price target on the stock.
• 11/6/2025 – Abivax was upgraded by analysts at Wolfe Research to a “strong-buy” rating.
• 11/5/2025 – Abivax is now covered by analysts at Wolfe Research. They set an “outperform” rating and a $176.00 price target on the stock.
• 11/4/2025 – Abivax had its “market outperform” rating reaffirmed by analysts at Citigroup Inc..

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.